文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿那白滞素联合标准治疗对重型COVID-19患者的疗效与安全性:一项随机2/3期临床试验

Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论在重型COVID-19肺炎伴高炎症反应住院患者中,阿那白滞素未能预防机械通气需求或降低死亡风险。

本研究为多中心、随机、开放标签、两组、2/3期临床试验,在西班牙12家医院纳入179例重型COVID-19肺炎伴高炎症反应的成人患者,随机分为阿那白滞素(100 mg每日4次静脉给药)联合标准治疗组(92例)和标准治疗组(87例)。主要终点为治疗开始后15天内无需机械通气的患者比例,两组无显著差异(阿那白滞素组64/83例[77.1%] vs 标准治疗组67/78例[85.9%];RR 0.90;95%CI 0.77-1.04;P=0.16)。至机械通气时间(HR 1.72;95%CI 0.82-3.62;P=0.14)及15天内无需有创机械通气比例(RR 0.99;95%CI 0.88-1.11;P>0.99)均无显著差异。结论认为,与单纯标准治疗相比,阿那白滞素未能预防机械通气需求或降低死亡风险。

要点

  • 阿那白滞素组15天内无需机械通气比例为77.1%(64/83),标准治疗组为85.9%(67/78),RR 0.90(95%CI 0.77-1.04),P=0.16,无显著差异。
  • 至机械通气时间风险比HR 1.72(95%CI 0.82-3.62),P=0.14,两组无显著差异。
  • 15天内无需有创机械通气比例RR 0.99(95%CI 0.88-1.11),P>0.99,无显著差异。
  • 高炎症反应定义为白介素-6>40 pg/mL、铁蛋白>500 ng/mL、C反应蛋白>3 mg/dL(依据≥5倍正常上限)和/或乳酸脱氢酶>300 U/L。
  • 重型肺炎定义为至少满足以下一项:室内空气下脉氧饱和度≤94%,氧分压/吸入氧浓度比≤300,和/或脉氧饱和度/吸入氧浓度比≤350。

适用人群与场景

  • 成人重型COVID-19肺炎伴高炎症反应的住院患者,来自西班牙12家医院。
  • 高炎症反应定义:白介素-6>40 pg/mL、铁蛋白>500 ng/mL、C反应蛋白>3 mg/dL(依据≥5倍正常上限)和/或乳酸脱氢酶>300 U/L。
  • 重型肺炎定义:至少满足以下一项:室内空气下脉氧饱和度≤94%,氧分压/吸入氧浓度比≤300,和/或脉氧饱和度/吸入氧浓度比≤350。

诊断标准与关键阈值

  • 高炎症反应:白介素-6>40 pg/mL、铁蛋白>500 ng/mL、C反应蛋白>3 mg/dL(依据≥5倍正常上限)和/或乳酸脱氢酶>300 U/L。
  • 重型肺炎:至少满足以下一项:室内空气下脉氧饱和度≤94%,氧分压/吸入氧浓度比≤300,和/或脉氧饱和度/吸入氧浓度比≤350。

处置流程与药物剂量

  • 阿那白滞素组:在常规标准治疗基础上加用阿那白滞素100 mg,每日4次,静脉给药。
  • 标准治疗组:仅给予常规标准治疗。

研究设计与关键结果

  • 研究设计:多中心、随机、开放标签、两组、2/3期临床试验(ANA-COVID-GEAS),在西班牙12家医院进行,2020年5月8日至2021年3月1日,随访1个月。
  • 样本量:179例成人患者(123例男性[69.9%];平均[标准差]年龄60.5[11.5]岁),随机分为阿那白滞素组92例和标准治疗组87例。
  • 主要终点:治疗开始后15天内无需机械通气的患者比例,阿那白滞素组64/83例(77.1%)vs 标准治疗组67/78例(85.9%),RR 0.90(95%CI 0.77-1.04),P=0.16,无显著差异。
  • 至机械通气时间:HR 1.72(95%CI 0.82-3.62),P=0.14,无显著差异。
  • 15天内无需有创机械通气比例:RR 0.99(95%CI 0.88-1.11),P>0.99,无显著差异。
  • 结论:阿那白滞素未能预防机械通气需求或降低死亡风险。

证据类型、等级与局限

  • 证据类型:随机、开放标签、多中心2/3期临床试验。
  • 试验注册号:ClinicalTrials.gov NCT04443881。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于重型COVID-19肺炎伴高炎症反应的住院成人患者,与单纯标准治疗相比,加用阿那白滞素100 mg每日4次静脉给药未能预防机械通气需求或降低死亡风险。
  • 原文未据此给出推荐。

指南或共识出处

  • 原文为研究论文,未引用指南或共识。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation are still unclear.

OBJECTIVE: To assess the efficacy and safety of anakinra vs standard of care alone for patients with severe COVID-19 pneumonia and hyperinflammation.

DESIGN, SETTING, AND PARTICIPANTS: The Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to COVID-19 (ANA-COVID-GEAS) was a multicenter, randomized, open-label, 2-group, phase 2/3 clinical trial conducted at 12 hospitals in Spain between May 8, 2020, and March 1, 2021, with a follow-up of 1 month. Participants were adult patients with severe COVID-19 pneumonia and hyperinflammation. Hyperinflammation was defined as interleukin-6 greater than 40 pg/mL, ferritin greater than 500 ng/mL, C-reactive protein greater than 3 mg/dL (rationale, ≥5 upper normal limit), and/or lactate dehydrogenase greater than 300 U/L. Severe pneumonia was considered if at least 1 of the following conditions was met: ambient air oxygen saturation 94% or less measured with a pulse oximeter, ratio of partial pressure O2 to fraction of inspired O2 of 300 or less, and/or a ratio of O2 saturation measured with pulse oximeter to fraction of inspired O2 of 350 or less. Data analysis was performed from April to October 2021.

INTERVENTIONS: Usual standard of care plus anakinra (anakinra group) or usual standard of care alone (SoC group). Anakinra was given at a dose of 100 mg 4 times a day intravenously.

MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-to-treat basis.

RESULTS: A total of 179 patients (123 men [69.9%]; mean [SD] age, 60.5 [11.5] years) were randomly assigned to the anakinra group (92 patients) or to the SoC group (87 patients). The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups (64 of 83 patients [77.1%] in the anakinra group vs 67 of 78 patients [85.9%] in the SoC group; risk ratio [RR], 0.90; 95% CI, 0.77-1.04; P = .16). Anakinra did not result in any difference in time to mechanical ventilation (hazard ratio, 1.72; 95% CI, 0.82-3.62; P = .14). There was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15 (RR, 0.99; 95% CI, 0.88-1.11; P > .99).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04443881.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, et al. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial. JAMA Netw Open. 2023. PMID: 37027155. doi:10.1001/jamanetworkopen.2023.7243

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。